Clinical Trial Update: Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating the weight-loss drug Orlistat (Xenical) for overweight patients with nonalcoholic steatohepatitis (NASH) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis
• Viral Hepatitis

Drugs mentioned

• Orlistat (Xenical) (orlistat)

Snippet

Sponsor: St. Louis University | Conditions: Fatty Liver, Hepatitis | Phase 4 | Status: COMPLETED